In-vitro activity of ciprofioxacin and other antibacterial agents against Pseudonwnas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients

Publisher Website
Google Scholar
Abstract
The in-vitro activities of ciprofloxacin, a new oxyquinoline derivative, norfioxacin and six anti-pseudomal β-lactam antibiotics were tested against pulmonary isolates of smooth and mucoid colony forms of Pseudomonas aeruginosa, and Ps. cepacia from children with cystic fibrosis. Ciprofloxacin was the most effective of the agents tested against either species Minimal inhibitory concentrations of ciprofloxacin were 0·5, and 16 mg/l, for 90% of the Ps. aeruginosa and Ps. cepacia strains tested, respectively. No effect of inoculum size or discordance between inhibitory or bactericidal concentrations was observed. Ciprofioxacin is a potentially useful agent for the treatment of acute pseudomonal pulmonary exacerbations in children with cystic fibrosis.